Explore strategies for controlling COPD and improving health, with a focus on management and lifestyle changes.

One of these methods, which has been used in the US and many European countries for some time now, has finally made its way ...

Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.

Among patients with COPD who experienced an exacerbation, the risk for cardiovascular events was highest in the following 2 weeks and stayed elevated more than 1 year after, according to study results ...

The outcomes of interest were MACE collectively and individual MACE subtypes. Measurements and main results Among 113 353 people with COPD (mean age 67.9 years old, 53.3% male), ICS prescription was ...

Ensifentrine is a promising supplementary therapeutic option in the management of chronic obstructive pulmonary disease (COPD), according to systematic review and meta-analysis findings published in ...

Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.

Expert pulmonologists share essential guidelines on distinguishing normal coughs from dangerous ones, plus effective home ...

What does that mean? If you’re an evidence-based thinker, it means nothing. If you’re a believer in astrology, however, it means I was born at a time of the year when the sun’s influence on ...

The U.S. Food and Drug Administration (FDA) has granted approval for Zepbound, a weight-loss medication, to treat moderate to severe obstructive sleep apnea (OSA) in individuals with obesity. This ...

Patients with COPD who also had prior asthma diagnoses were included in ... We assessed socioeconomic covariates (mean copayments, total copayments, and unique brand-to-generic prescription fills) ...